Primary IgA Nephropathy Clinical Trial
Official title:
An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon. During Study Nef-301 OLE, the patients and Investigators will remain blinded to treatment given in Study Nef-301. During Study Nef-301 OLE, patients will receive Nefecon for a 9-month period. The dose may be reduced if clinically relevant adverse events (AEs) develop during the 9-month Treatment Period that the Investigator considers related to the study drug and that mandate dose reduction. Patients will remain on a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) throughout the study. The patient will come for a follow-up visit at 12 months after first dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03643965 -
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
|
Phase 3 | |
| Recruiting |
NCT04557462 -
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
|
Phase 3 | |
| Recruiting |
NCT05847920 -
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
|
Phase 2 | |
| Recruiting |
NCT02765594 -
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
|
Phase 4 | |
| Not yet recruiting |
NCT02712697 -
Integrative Medicine of IgA Nephropathy
|
N/A | |
| Completed |
NCT04887532 -
A Trial of HR19042 Capsule in Healthy Chinese Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06137768 -
A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
|
Phase 2 | |
| Completed |
NCT02351752 -
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
|
Phase 4 | |
| Active, not recruiting |
NCT04014335 -
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
|
Phase 2 | |
| Completed |
NCT01738035 -
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
|
Phase 2 | |
| Recruiting |
NCT05797610 -
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
|
Phase 3 |